25 related articles for article (PubMed ID: 20071597)
1. Quality of life in patients treated with first-line antiretroviral therapy containing nevirapine or efavirenz in Uganda: a prospective non-randomized study.
Mwesigire DM; Wu AW; Martin F; Katamba A; Seeley J
BMC Health Serv Res; 2015 Jul; 15():292. PubMed ID: 26216221
[TBL] [Abstract][Full Text] [Related]
2. Multicenter study of skin rashes and hepatotoxicity in antiretroviral-naïve HIV-positive patients receiving non-nucleoside reverse-transcriptase inhibitor plus nucleoside reverse-transcriptase inhibitors in Taiwan.
Wu PY; Cheng CY; Liu CE; Lee YC; Yang CJ; Tsai MS; Cheng SH; Lin SP; Lin DY; Wang NC; Lee YC; Sun HY; Tang HJ; Hung CC
PLoS One; 2017; 12(2):e0171596. PubMed ID: 28222098
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of non-nucleoside reverse-transcriptase inhibitor-based antiretroviral therapy in women previously exposed to a single intrapartum dose of nevirapine: a multi-country, prospective cohort study.
Stringer JS; McConnell MS; Kiarie J; Bolu O; Anekthananon T; Jariyasethpong T; Potter D; Mutsotso W; Borkowf CB; Mbori-Ngacha D; Muiruri P; Ong'ech JO; Zulu I; Njobvu L; Jetsawang B; Pathak S; Bulterys M; Shaffer N; Weidle PJ
PLoS Med; 2010 Feb; 7(2):e1000233. PubMed ID: 20169113
[TBL] [Abstract][Full Text] [Related]
4. Targeted maximum likelihood estimation of effect modification parameters in survival analysis.
Stitelman OM; Wester CW; De Gruttola V; van der Laan MJ
Int J Biostat; 2011 Mar; 7(1):19. PubMed ID: 21556287
[TBL] [Abstract][Full Text] [Related]
5. A model and risk score for predicting nevirapine-associated rash among HIV-infected patients: in settings of low CD4 cell counts and resource limitation.
Kiertiburanakul S; Sungkanuparph S; Malathum K; Watcharananan S; Sathapatayavongs B; Charoenyingwattana A; Mahasirimongkol S; Chantratita W
Open AIDS J; 2009 Jul; 3():24-30. PubMed ID: 19639037
[TBL] [Abstract][Full Text] [Related]
6. Choice of initial antiretroviral drugs and treatment outcomes among HIV-infected patients in sub-Saharan Africa: systematic review and meta-analysis of observational studies.
Ayele TA; Worku A; Kebede Y; Alemu K; Kasim A; Shkedy Z
Syst Rev; 2017 Aug; 6(1):173. PubMed ID: 28841912
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose efavirenz vs. standard-dose nevirapine in antiretroviral regimens among HIV-1 and tuberculosis co-infected patients who received rifampicin.
Manosuthi W; Mankatitham W; Lueangniyomkul A; Chimsuntorn S; Sungkanuparph S
HIV Med; 2008 May; 9(5):294-9. PubMed ID: 18400076
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing plasma drug concentrations and efficacies between 2 nonnucleoside reverse-transcriptase inhibitor-based regimens in HIV-infected patients receiving rifampicin: the N2R Study.
Manosuthi W; Sungkanuparph S; Tantanathip P; Lueangniyomkul A; Mankatitham W; Prasithsirskul W; Burapatarawong S; Thongyen S; Likanonsakul S; Thawornwa U; Prommool V; Ruxrungtham K;
Clin Infect Dis; 2009 Jun; 48(12):1752-9. PubMed ID: 19438397
[TBL] [Abstract][Full Text] [Related]
10. Nevirapine versus efavirenz based antiretroviral treatment in naive Indian patients: comparison of effectiveness in clinical cohort.
Patel AK; Pujari S; Patel K; Patel J; Shah N; Patel B; Gupte N
J Assoc Physicians India; 2006 Dec; 54():915-8. PubMed ID: 17334006
[TBL] [Abstract][Full Text] [Related]
11. Simplification of protease inhibitor-containing regimens with efavirenz, nevirapine or abacavir: safety and efficacy outcomes.
Chiesa E; Bini T; Adorni F; Capetti A; Rizzardini G; Faggion I; Mussini C; Sollima S; Melzi S; Bongiovanni M; Tordato F; Cicconi P; Castelnuovo B; Rusconi S; d'Arminio Monforte A
Antivir Ther; 2003 Feb; 8(1):27-35. PubMed ID: 12713061
[TBL] [Abstract][Full Text] [Related]
12. Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone.
Chimsuntorn S; Sungkanuparph S; Manosuthi W
J Int Assoc Physicians AIDS Care (Chic); 2010; 9(1):43-5. PubMed ID: 20071597
[TBL] [Abstract][Full Text] [Related]
13. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
